SUMMARY During a screening programme of 10 000 pregnant women by the Guthrie test, a previously unrecognised phenylketonuric woman was detected. A low phenylalanine diet introduced from the 16th week of gestation failed to prevent fetal abnormality and mental retardation. Maternal phenylketonuria requires earlier diagnosis than can be achieved at the initial antenatal clinic visit if its teratogenic effects are to be prevented.
Women with phenylketonuria (PKU) run a high risk of giving birth to infants with intrauterine growth retardation, mental retardation, microcephaly, or congenital heart disease.' The possibility that a low phenylalanine diet started in early pregnancy might protect the fetus from the harmful effects of maternal PKU during the rest of the pregnancy led to a pilot scheme by the PKU screening laboratory at Stobhill Hospital, and 10 000 pregnant women were screened for hyperphenylalaninaemia by the Guthrie test. Among those screened was a 27-year-old primigravida, who, when she booked for hospital confinement at 11 weeks' gestation, had a blood phenylalanine level above 20 mg/100 ml (>1 2 mmol/l). She was started on a low phenylalanine diet at 16 weeks' gestation (14 weeks from conception) and continued on this diet until she gave birth to a light-for-dates infant who was microcephalic and had the Pierre Robin syndrome.
Case report
A 27-year-old primigravida booked for hospital confinement at 11 weeks' gestation. She had fair hair and blue eyes, her height was 154 cm and her weight 57 kg. Her IQ (Weschler adult intelligence scale) was 92, with a verbal subscale of 99 and a performance subscale of 84. Blood phenylalanine by the Guthrie test was above 20 mg/100 ml. Serum phenylalanine concentration by chromatography was 22*3 mg/100 ml (1 *35 mmol/l) and serum tyrosine 0-048 mmol/l. Her urine contained phenylpyruvic acid and o-hydroxyphenylacetic acid.
A low phenylalanine diet was started at 16 weeks and adhered to during the rest of her pregnancy. Blood phenylalanine levels were monitored by twice-weekly Guthrie tests and serum phenylalanine levels were determined by fluorimetry monthly, or when indicated by the Guthrie test. Between the 19th and 22nd weeks of gestation levels of <2 mg/100 ml (0.12 mmol/l) were detected by the Guthrie method. However, fluorimetric estimation of phenylalanine at 21 weeks was 1 9 mg/100 ml (0-11 mmol/l) and again at 22 weeks was 2'7 mg/100ml(0 16mmol/l). Thereafter, with three exceptions, Guthrie levels varied between 4 mg/100 ml (0 2 mmol/l) and 10 mg/100 ml (0* 6 mmol/l) (Fig. 1 Maternalphenylketonuria: abnoufmal baby despite low phenylalanine diet during pregnancy 635 meconium-stained liquor and a Kielland's rotation and delivery were performed when fetal tachycardia developed during the second stage.
The baby had a one-minute Apgar score of 5, and regular breathing was established by 3 minutes. He weighed 2 -72 kg (< 10th centile on the Gairdner and Pearson chart) (Fig. 2) , occipitofrontal circum-7 ference was 33 cm (<1Oth centile), and he was found to have a hypoplastic mandible ( Fig. 3 ) with a posterior cleft palate. He began bottle feeding with Ostermilk Complete formula, but feeding difficulties due to respiratory difficulty were evident from birth, and each feed took between 60 and 90 minutes.
Guthrie tests at 2 and 8 days gave phenylalanine levels of 2 mg/100 ml, while his mother, now taking an ordinary diet, had reverted to hyperphenylalinaemia (1 -6 mmol/l). At outpatient review, aged 17 days, his weight had fallen to 2 65 kg and he was admitted to hospital because of persistent failure to complete feeds. Nasogastric feeding did not produce a significant weight gain and was abandoned in favour of spoon feeding. On discharge aged 2 months, length, weight, and occipitofrontal circumference were each <3rd centile with no evidence of catch-up growth at 18 months (Fig. 2) Edinburgh Successfully treated PKU girls are reaching childbearing age. The number will grow even faster as those who were diagnosed by the Guthrie test reach maturity. Many have already stopped the diet. Most are eligible for marriage and some may believe that they will have normal children if they return to diet before or during pregnancy. Early experience of such dietary manipulation must make us pause and consider. It ranges in Britain from some reassuring success to rather more disturbing failure without suggesting a clear reason for the difference. The above case falls into the unsuccessful group and even in the recent series from Manchester,' success, although impressive at an early stage in developmental testing, is not perfect. Buist et al. in Oregon2 similarly have had mixed fortunes with a small group in whom the maternal serum phenylalanine was controlled from 8 to 30 weeks of gestation.
A worldwide review of phenylketonuric pregnancies was presented by Lenke and Levy3 at a meeting of the American Society of Human Genetics. In untreated pregnancies, in which the maternal serum phenylalanine level exceeded 1 2 mmol/l, microcephaly and mental retardation occurred in 90 %. When the maternal level lay between 0 * 96 and 1 2 mmol/l they were found in 75% of children. Congenital heart disease was also present in many. It was concluded that treatment started after conception but before the 20th gestational week prevented microcephaly but not congenital heart disease. Recently Nielsen et al.4 reported the birth of an apparently normal baby to a relatively mild phenylketonuric woman whose blood phenylalanine level was held in an acceptable range (0 48 to 0-61 mmol/l) before conception and in the range 0' 18 to 0*48 mmol/l from conception to delivery.
So far no absolutely consistent relationship has emerged between outcome and maternal serum phenylalanine level (or urinary phenylketones) at conception or later, the week of pregnancy at which control was achieved, age, or maternal intelligence. Future studies must ensure that there are no other fetal insults in each pregnancy. They will need to identify, if possible, the defect in maternal phenylalanine metabolism (including the rare biopterin deficiency).
They will need to document phenylalanine levels during the prenatal weeks and throughout pregnancy and to record levels below 0 12 mmol/l as carefully as those above 0 * 6 mmol/l. Those with expertise in transplacental nutrition should examine the possibility that the low phenylalanine diet may impair fetal growth and development. Aborted fetuses should not be discarded without careful examination. It seems unlikely that poor PKU control in childhood and adolescence could by itself be mutagenic. Experience may now grow quickly and must be shared. The wiser PKU women may prefer to delay child bearing for a few more years until better informed advice can be given. The recent discovery5 that phenylalanine ammonia lyase (or PAL) may enable a PKU woman to eat a relatively normal diet while maintaining normal blood phenylalanine levels could greatly facilitate prepregnancy and pregnancy control. 
